최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Der Radiologe, v.57 no.10, 2017년, pp.840 - 849
Widmann, G. , Nguyen, V. A. , Plaickner, J. , Jaschke, W.
초록이 없습니다.
Ther Adv Respir Dis O Abdel-Rahman 10 183 2016 10.1177/1753465816636557 Abdel-Rahman O, Fouad M (2016) Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis 10:183-193
Eur J Endocrinol F Albarel 172 195 2015 10.1530/EJE-14-0845 Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172:195-204
J Endocrinol Invest PB Araujo 38 11 1159 2015 10.1007/s40618-015-0301-z Araujo PB, Coelho MC, Arruda M et al (2015) Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38(11):1159-1166. doi: 10.1007/s40618-015-0301-z
Abdom Radiol (NY) AR Barina 41 2 207 2016 10.1007/s00261-015-0560-3 Barina AR, Bashir MR, Howard BA et al (2016) Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY) 41(2):207-214. doi: 10.1007/s00261-015-0560-3
Korean J Radiol M Braschi-Amirfarzan 18 42 2017 10.3348/kjr.2017.18.1.42 Braschi-Amirfarzan M, Tirumani SH, Hodi FS Jr. et al (2017) Immune-checkpoint inhibitors in the era of precision medicine: What radiologists should know. Korean J Radiol 18:42-53
AJR Am J Roentgenol Y Bronstein 197 W992 2011 10.2214/ajr.10.6198 Bronstein Y, Ng CS, Hwu P et al (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992-W1000. doi: 10.2214/ajr.10.6198
Ann Rheum Dis LC Cappelli 76 1 43 2017 10.1136/annrheumdis-2016-209595 Cappelli LC, Gutierrez AK, Baer AN et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76(1):43-50. doi: 10.1136/annrheumdis-2016-209595
J Immunother MM Chan 38 37 2015 10.1097/CJI.0000000000000060 Chan MM, Kefford RF, Carlino M et al (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38:37-39
J. Gastroenterol. Hepatol. R Cheng 30 657 2015 10.1111/jgh.12888 Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30:657-666
Clin Neurol Neurosurg Y Chodakiewitz 125 125 2014 10.1016/j.clineuro.2014.06.011 Chodakiewitz Y, Brown S, Boxerman JL et al (2014) Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg 125:125-130. doi: 10.1016/j.clineuro.2014.06.011
Curr Gastroenterol Rep P Cramer 19 1 3 2017 10.1007/s11894-017-0540-6 Cramer P, Bresalier RS (2017) Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 19(1):3. doi: 10.1007/s11894-017-0540-6
Physiol Res R Demlova 65 S455 2016 10.33549/physiolres.933525 Demlova R, Valik D, Obermannova R et al (2016) The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiol Res 65:S455-S462
Cancer Imaging S Diederich 16 7 2016 10.1186/s40644-016-0066-4 Diederich S (2016) Chest CT for suspected pulmonary complications of oncologic therapies: How I review and report. Cancer Imaging 16:7
J Clin Endocrinol Metab AT Faje 99 11 4078 2014 10.1210/jc.2014-2306 Faje AT, Sullivan R, Lawrence D et al (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99(11):4078-4085. doi: 10.1210/jc.2014-2306
Curr Opin Oncol L Heinzerling 29 136 2017 10.1097/CCO.0000000000000358 Heinzerling L, Goldinger SM (2017) A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol 29:136-144
Invest New Drugs KW Kim 31 4 1071 2013 10.1007/s10637-013-9939-6 Kim KW, Ramaiya NH, Krajewski KM et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31(4):1071-1077. doi: 10.1007/s10637-013-9939-6
AJR Am J Roentgenol KW Kim 200 5 W468 2013 10.2214/ajr.12.9751 Kim KW, Ramaiya NH, Krajewski KM et al (2013) Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 200(5):W468-W474. doi: 10.2214/ajr.12.9751
Immunotherapy HR Kourie 8 7 799 2016 10.2217/imt-2016-0029 Kourie HR, Klastersky J (2016) Immune checkpoint inhibitors side effects and management. Immunotherapy 8(7):799-807. doi: 10.2217/imt-2016-0029
Front Pharmacol V Kumar 8 49 2017 10.3389/fphar.2017.00049 Kumar V, Chaudhary N, Garg M et al (2017) Current diagnosis and management of immune related adverse events (irAes) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49
Radiographics JJ Kwak 35 2 424 2015 10.1148/rg.352140121 Kwak JJ, Tirumani SH, Van Den Abbeele AD et al (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35(2):424-437. doi: 10.1148/rg.352140121
Pharmacotherapy NM La-Beck 35 10 963 2015 10.1002/phar.1643 La-Beck NM, Jean GW, Huynh C et al (2015) Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 35(10):963-976. doi: 10.1002/phar.1643
N Engl J Med J Larkin 373 13 1270 2015 10.1056/nejmc1509660 Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(13):1270-1271. doi: 10.1056/nejmc1509660
Medicine (Baltimore) CS Lu 96 1 e5747 2017 10.1097/md.0000000000005747 Lu CS, Liu JH (2017) Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports. Medicine (Baltimore) 96(1):e5747. doi: 10.1097/md.0000000000005747
Endocrine J Marlier 47 878 2014 10.1007/s12020-014-0199-9 Marlier J, Cocquyt V, Brochez L et al (2014) Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine 47:878-883
Clin Cancer Res M Nishino 22 24 6051 2016 10.1158/1078-0432.ccr-16-1320 Nishino M, Ramaiya NH, Awad MM et al (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22(24):6051-6060. doi: 10.1158/1078-0432.ccr-16-1320
Cancer Treat Rev L Spain 44 51 2016 10.1016/j.ctrv.2016.02.001 Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51-60
Arthritis Rheumatol ME Suarez-Almazor 69 4 687 2017 10.1002/art.40043 Suarez-Almazor ME, Kim ST, Abdel-Wahab N et al (2017) Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 69(4):687-699. doi: 10.1002/art.40043
Cancer Immunol Res SH Tirumani 3 10 1185 2015 10.1158/2326-6066.cir-15-0102 Tirumani SH, Ramaiya NH, Keraliya A et al (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3(10):1185-1192. doi: 10.1158/2326-6066.cir-15-0102
BMC Cancer O Venditti 15 87 2015 10.1186/s12885-015-1074-7 Venditti O, De Lisi D, Caricato M et al (2015) Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer 15:87
Allergol Int S Watanabe 65 487 2016 10.1016/j.alit.2016.04.009 Watanabe S, Kimura H, Takato H et al (2016) Severe pneumonitis after nivolumab treatment in a patient with melanoma. Allergol Int 65:487-489
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.